long term glp 1 use effects of Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Long-term Success of GLP-1s Hinges

Biological interest in the DPP-4 enzyme has heightened after the discovery and approval of highly selective DPP-4 inhibitors (agents that selectively inactivate DPP-4 and augment the incretin effect) for the treatment of type 2 diabetes [42,43]

Diabetes Metab Syndr Obes, 2020

Combination Therapy Empagliflozin can also play a critical role as part of combination therapy, which involves using multiple medications to manage type 2 diabetes

In this manuscript we report: 1) for the first time our findings on the (3 + 2) methodology, 2) expanded substrate scope for the (4 + 3) annulation, 3) the identification of one of these compounds, JWU-A021, as a potent GLP-1 secretagogue, and 4) experimental evidence indicating that JWU-A021 likely operates in the intestinal L-cells by elevating the intracellular [Ca 2+ ] by means of activating the Transient Receptor Potential Ankyrin 1 channel (TRPA1) 4

instead, they should only progress to an increased dose when tolerance is demonstrated